Table 1. Incidence rate of sequential HPV infection in the anus for participants with or without previous genital HPV infection of the same type by sex in Liuzhou, China, 2014–2016*.
| HPV status at genital site before anal infection | Positive for HPV type at anal site |
||||||
|---|---|---|---|---|---|---|---|
| Men |
Women |
||||||
| No. | Incidence/1,000 person-months (95% CI) | HR (95% CI) | No. | Incidence/1,000 person-months (95% CI) | HR (95% CI) | ||
| Any HPV | |||||||
| Negative | 52 | 3.8 (2.9–4.9) | 1.0 | 149 | 6.2 (5.3–7.3) | 1.0 | |
| Positive |
14 |
8.8 (5.2–14.8) |
2.6 (1.4–4.6) |
|
87 |
25.9 (21.0–31.9) |
4.4 (3.4–5.8) |
| High-risk HPV | |||||||
| Negative | 33 | 2.4 (1.7–3.3) | 1.0 | 136 | 5.6 (4.8–6.7) | 1.0 | |
| Positive |
13 |
8.9 (5.2–15.4) |
4.2 (2.2–8.0) |
|
82 |
25.2 (20.3–31.3) |
4.7 (3.6–6.2) |
| 9V-HPV | |||||||
| Negative | 35 | 2.5 (1.8–3.5) | 1.0 | 69 | 2.8 (2.2–3.6) | 1.0 | |
| Positive |
5 |
6.0 (2.5–14.3) |
2.8 (1.1–6.9) |
|
32 |
19.8 (14.0–28.0) |
7.6 (5.0–11.5) |
| HPV 16/18 | |||||||
| Negative | 7 | 0.5 (0.2–1.1) | 1.0 | 20 | 0.8 (0.5–1.3) | 1.0 | |
| Positive |
1 |
3.7 (0.5–26.0) |
10.4 (1.3–85.9) |
|
11 |
16.9 (9.4–30.5) |
25.4 (12.0–53.6) |
| HPV 6/11 | |||||||
| Negative | 20 | 1.4 (0.9–2.2) | 1.0 | 13 | 0.5 (0.3–0.9) | 1.0 | |
| Positive | 1 | 5.4 (0.8–38.7) | 4.0 (0.5–30.5) | 3 | 15.6 (5.0–48.3) | 35.4 (9.9–126.9) | |
| HPV 6 | |||||||
| Negative | 10 | 0.7 (0.4–1.3) | 1.0 | 8 | 0.3 (0.2–0.7) | 1.0 | |
| Positive |
1 |
9.6 (1.4–68.2) |
11.9 (1.5–96.2) |
|
2 |
27.5 (6.9–110.1) |
95.2 (19.7–459.9) |
| HPV 11 | |||||||
| Negative | 11 | 0.8 (0.4–1.4) | NE | 5 | 0.2 (0.1–0.5) | 1.0 | |
| Positive |
0 |
0 |
NE |
|
1 |
7.8 (1.1–55.3) |
43.7 (5.1–375.1) |
| HPV 16 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 11 | 0.5 (0.3–0.8) | 1.0 | |
| Positive |
1 |
6.7 (0.9–47.5) |
52.4 (4.7–584.6) |
|
8 |
16.9 (8.5–33.9) |
45.8 (17.9–117.1) |
| HPV 18 | |||||||
| Negative | 5 | 0.4 (0.2–0.9) | NE | 9 | 0.4 (0.2–0.7) | 1.0 | |
| Positive |
0 |
0 |
NE |
|
3 |
13.5 (4.4–42.0) |
38.0 (10.3–140.6) |
| HPV 31 | |||||||
| Negative | 0 | 0 | NE | 2 | 0.1 (0.0–0.3) | 1.0 | |
| Positive |
0 |
0 |
NE |
|
3 |
22.1 (7.1–68.7) |
289.6 (48.2–1,740.9) |
| HPV 33 | |||||||
| Negative | 4 | 0.3 (0.1–0.8) | 1.0 | 12 | 0.5 (0.3–0.9) | 1.0 | |
| Positive |
1 |
12.4 (1.7–88.2) |
71.9 (7.4–700.0) |
|
5 |
30.0 (12.5–72.1) |
68.3 (23.9–194.9) |
| HPV 35 | |||||||
| Negative | 1 | 0.1 (0.0–0.5) | 1.0 | 3 | 0.1 (0.0–0.4) | 1.0 | |
| Positive |
1 |
19.0 (2.7–134.5) |
279.0 (17.2–4,524.7) |
|
2 |
13.1 (3.3–52.4) |
148.5 (20.8–1,058.9) |
| HPV 39 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 17 | 0.7 (0.4–1.2) | 1.0 | |
| Positive |
2 |
9.7 (2.4–38.8) |
57.4 (8.0–408.9) |
|
15 |
34.6 (20.9–57.4) |
46.0 (22.6–93.9) |
| HPV 45 | |||||||
| Negative | 1 | 0.1 (0.0–0.5) | 1.0 | 1 | 0.0 (0.0–0.3) | NE | |
| Positive |
1 |
36.5 (5.1–258.8) |
381.9 (23.9–6,105.8) |
|
0 |
0 |
NE |
| HPV 51 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 15 | 0.6 (0.4–1.0) | 1.0 | |
| Positive |
1 |
11.8 (1.7–83.6) |
84.0 (7.6–9,277.9) |
|
4 |
21.8 (8.2–58.1) |
40.9 (13.4–124.8) |
| HPV 52 | |||||||
| Negative | 8 | 0.6 (0.3–1.2) | 1.0 | 41 | 1.8 (1.3–2.5) | 1.0 | |
| Positive |
3 |
9.2 (3.0–28.4) |
15.9 (4.2–60.1) |
|
29 |
25.5 (17.7–36.7) |
14.7 (9.1–23.7) |
| HPV 56 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 6 | 0.2 (0.1–0.6) | 1.0 | |
| Positive |
1 |
8.7 (1.2–61.9) |
127.6 (8.0–2,039.7) |
|
4 |
18.9 (7.1–50.3) |
160.2 (39.4–650.7) |
| HPV 58 | |||||||
| Negative | 5 | 0.4 (0.2–0.9) | 1.0 | 24 | 1.0 (0.7–1.5) | 1.0 | |
| Positive |
1 |
2.9 (0.4–20.9) |
8.6 (0.99–74.7) |
|
11 |
20.4 (11.3–36.9) |
20.7 (10.1–42.3) |
| HPV 59 | |||||||
| Negative | 3 | 0.2 (0.1–0.7) | 1.0 | 10 | 0.4 (0.2–0.8) | 1.0 | |
| Positive |
1 |
10.0 (1.4–71.3) |
48.5 (5.0–467.3) |
|
8 |
30.4 (15.2–60.8) |
69.8 (27.0–180.7) |
| HPV 66 | |||||||
| Negative | 0 | 0 | NE | 5 | 0.2 (0.1–0.5) | 1.0 | |
| Positive |
0 |
0 |
NE |
|
2 |
18.2 (4.5–72.7) |
83.3 (16.1–430.0) |
| HPV 68 | |||||||
| Negative | 0 | 0 | NE | 0 | 0 | NE | |
| Positive | 0 | NE | NE | 0 | NE | NE | |
*HRs and 95% CIs of sequential grouped HPV infection were calculated based on individual results. 9V-HPV, 9-valent vaccine-related HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58); HR-HPV, high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68); HPV, human papillomavirus; HR, hazard ratio; NE, not estimable..